JPMorgan Chase & Co. Raises Humana (NYSE:HUM) Price Target to $393.00

Humana (NYSE:HUM) had its price target hoisted by equities researchers at JPMorgan Chase & Co. from $316.00 to $393.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a “neutral” rating on the insurance provider’s stock. JPMorgan Chase & Co.‘s price target points to a potential upside of 1.74% from the company’s current price.

Several other equities analysts have also recently commented on the stock. Royal Bank Of Canada lifted their target price on shares of Humana from $246.00 to $415.00 and gave the stock a “sector perform” rating in a research report on Thursday, July 9th. Zacks Research raised Humana from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. Wells Fargo & Company raised Humana from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $227.00 to $502.00 in a research report on Monday, July 13th. Guggenheim lifted their price target on Humana from $269.00 to $471.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Finally, Cantor Fitzgerald boosted their price objective on Humana from $264.00 to $300.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Humana presently has a consensus rating of “Moderate Buy” and an average target price of $395.22.

Humana Stock Up 0.3%

Humana stock traded up $1.29 during midday trading on Monday, reaching $386.29. The stock had a trading volume of 805,688 shares, compared to its average volume of 1,797,993. Humana has a 12 month low of $163.11 and a 12 month high of $428.88. The company has a fifty day moving average price of $377.18 and a two-hundred day moving average price of $271.64. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $46.39 billion, a P/E ratio of 36.60, a PEG ratio of 2.20 and a beta of 0.72.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, July 29th. The insurance provider reported $7.61 EPS for the quarter, beating analysts’ consensus estimates of $7.27 by $0.34. Humana had a net margin of 0.88% and a return on equity of 11.20%. The business had revenue of $40.89 billion during the quarter, compared to analyst estimates of $40.58 billion. During the same quarter in the previous year, the business posted $6.27 EPS. Humana’s quarterly revenue was up 26.2% on a year-over-year basis. As a group, equities analysts expect that Humana will post 9.08 EPS for the current fiscal year.

Institutional Trading of Humana

Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. purchased a new position in Humana in the second quarter worth $4,138,160,000. Pzena Investment Management LLC bought a new position in Humana in the second quarter valued at $1,749,014,000. Capital International Investors raised its position in Humana by 113.9% during the fourth quarter. Capital International Investors now owns 5,818,008 shares of the insurance provider’s stock valued at $1,490,239,000 after purchasing an additional 3,097,571 shares in the last quarter. Norges Bank purchased a new stake in Humana during the fourth quarter valued at about $456,632,000. Finally, Wellington Management Group LLP lifted its stake in Humana by 4,481.7% during the fourth quarter. Wellington Management Group LLP now owns 1,196,502 shares of the insurance provider’s stock worth $306,460,000 after purchasing an additional 1,170,387 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.